Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 7 Sept 2026Clinical review pending
!
Papilloedema is a sign requiring urgent explanation
Disc swelling caused by raised intracranial pressure can accompany a mass, cerebral venous thrombosis, hydrocephalus or another serious intracranial disorder.
Action: Arrange urgent hospital assessment with neuroimaging and ophthalmic evaluation. Reduced consciousness, rapidly worsening vision or focal neurological findings require immediate escalation. Do not perform a diagnostic lumbar puncture before appropriate imaging and assessment of procedural safety.
Synopsis
Confirm true optic-disc swelling from raised intracranial pressure, prioritise safe investigation of secondary causes, and protect visual function while managing idiopathic intracranial hypertension when established.
Papilloedema specifically means optic-disc swelling due to raised intracranial pressure; not every swollen-looking disc has this cause.
Early central acuity can remain good despite enlarged blind spots or developing peripheral field loss.
Confirm the disc findings, measure blood pressure and document acuity, pupils and formal visual fields.
Key red flags
Declining consciousness, a new focal deficit, seizure or rapidly progressive headache with disc swelling requires emergency neurological assessment.
Investigation priorities
01
Blood pressure and urgent ophthalmic assessmentFirst step
Identify severe hypertension and document visual risk accurately.
Management branches
New disc swellingConfirm the finding and investigate urgently
Papilloedema is suspected on examination or accompanied by relevant visual or neurological symptoms.
Arrange urgent ophthalmic and neurological assessment, documenting blood pressure, vision and any immediate neurological danger signs.
Obtain appropriate brain and venous imaging before lumbar puncture, escalating immediately rather than using a twenty-four-hour window for a deteriorating patient.
Key medicines
Acetazolamide for specialist-managed IIHThe UK consensus describes a common oral starting regimen of 250–500 mg twice daily, with subsequent clinician-directed titration according to response and tolerance. The optimal dose and treatment duration are not established, so continuation is reviewed against visual findings and adverse effects.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.